Cargando…
Development and Validation of a Nomogram Based on Metabolic Risk Score for Assessing Lymphovascular Space Invasion in Patients with Endometrial Cancer
Objective: This study assessed the predictive value of the metabolic risk score (MRS) for lymphovascular space invasion (LVSI) in endometrial cancer (EC) patients. Methods: We included 1076 patients who were diagnosed with EC between January 2006 and December 2020 in Peking University People’s Hospi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736227/ https://www.ncbi.nlm.nih.gov/pubmed/36497730 http://dx.doi.org/10.3390/ijerph192315654 |
_version_ | 1784846971377287168 |
---|---|
author | Wang, Jingyuan Li, Xingchen Yang, Xiao Wang, Jianliu |
author_facet | Wang, Jingyuan Li, Xingchen Yang, Xiao Wang, Jianliu |
author_sort | Wang, Jingyuan |
collection | PubMed |
description | Objective: This study assessed the predictive value of the metabolic risk score (MRS) for lymphovascular space invasion (LVSI) in endometrial cancer (EC) patients. Methods: We included 1076 patients who were diagnosed with EC between January 2006 and December 2020 in Peking University People’s Hospital. All patients were randomly divided into the training and validation cohorts in a ratio of 2:1. Data on clinicopathological indicators were collected. Univariable and multivariable logistic regression analysis was used to define candidate factors for LVSI. A backward stepwise selection was then used to select variables for inclusion in a nomogram. The performance of the nomogram was evaluated by discrimination, calibration, and clinical usefulness. Results: Independent predictors of LVSI included differentiation grades (G2: OR = 1.800, 95% CI: 1.050–3.070, p = 0.032) (G3: OR = 3.49, 95% CI: 1.870–6.520, p < 0.001), histology (OR = 2.723, 95% CI: 1.370–5.415, p = 0.004), MI (OR = 4.286, 95% CI: 2.663–6.896, p < 0.001), and MRS (OR = 1.124, 95% CI: 1.067–1.185, p < 0.001) in the training cohort. A nomogram was established to predict a patient’s probability of developing LVSI based on these factors. The ROC curve analysis showed that an MRS-based nomogram significantly improved the efficiency of diagnosing LVSI compared with the nomogram based on clinicopathological factors (p = 0.0376 and p = 0.0386 in the training and validation cohort, respectively). Subsequently, the calibration plot showed a favorable consistency in both groups. Moreover, we conducted a decision curve analysis, showing the great clinical benefit obtained from the application of our nomogram. However, our study faced several limitations. Further external validation and a larger sample size are needed in future studies. Conclusion: MRS-based nomograms are useful for predicting LVSI in patients with EC and may facilitate better clinical decision-making. |
format | Online Article Text |
id | pubmed-9736227 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97362272022-12-11 Development and Validation of a Nomogram Based on Metabolic Risk Score for Assessing Lymphovascular Space Invasion in Patients with Endometrial Cancer Wang, Jingyuan Li, Xingchen Yang, Xiao Wang, Jianliu Int J Environ Res Public Health Article Objective: This study assessed the predictive value of the metabolic risk score (MRS) for lymphovascular space invasion (LVSI) in endometrial cancer (EC) patients. Methods: We included 1076 patients who were diagnosed with EC between January 2006 and December 2020 in Peking University People’s Hospital. All patients were randomly divided into the training and validation cohorts in a ratio of 2:1. Data on clinicopathological indicators were collected. Univariable and multivariable logistic regression analysis was used to define candidate factors for LVSI. A backward stepwise selection was then used to select variables for inclusion in a nomogram. The performance of the nomogram was evaluated by discrimination, calibration, and clinical usefulness. Results: Independent predictors of LVSI included differentiation grades (G2: OR = 1.800, 95% CI: 1.050–3.070, p = 0.032) (G3: OR = 3.49, 95% CI: 1.870–6.520, p < 0.001), histology (OR = 2.723, 95% CI: 1.370–5.415, p = 0.004), MI (OR = 4.286, 95% CI: 2.663–6.896, p < 0.001), and MRS (OR = 1.124, 95% CI: 1.067–1.185, p < 0.001) in the training cohort. A nomogram was established to predict a patient’s probability of developing LVSI based on these factors. The ROC curve analysis showed that an MRS-based nomogram significantly improved the efficiency of diagnosing LVSI compared with the nomogram based on clinicopathological factors (p = 0.0376 and p = 0.0386 in the training and validation cohort, respectively). Subsequently, the calibration plot showed a favorable consistency in both groups. Moreover, we conducted a decision curve analysis, showing the great clinical benefit obtained from the application of our nomogram. However, our study faced several limitations. Further external validation and a larger sample size are needed in future studies. Conclusion: MRS-based nomograms are useful for predicting LVSI in patients with EC and may facilitate better clinical decision-making. MDPI 2022-11-25 /pmc/articles/PMC9736227/ /pubmed/36497730 http://dx.doi.org/10.3390/ijerph192315654 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wang, Jingyuan Li, Xingchen Yang, Xiao Wang, Jianliu Development and Validation of a Nomogram Based on Metabolic Risk Score for Assessing Lymphovascular Space Invasion in Patients with Endometrial Cancer |
title | Development and Validation of a Nomogram Based on Metabolic Risk Score for Assessing Lymphovascular Space Invasion in Patients with Endometrial Cancer |
title_full | Development and Validation of a Nomogram Based on Metabolic Risk Score for Assessing Lymphovascular Space Invasion in Patients with Endometrial Cancer |
title_fullStr | Development and Validation of a Nomogram Based on Metabolic Risk Score for Assessing Lymphovascular Space Invasion in Patients with Endometrial Cancer |
title_full_unstemmed | Development and Validation of a Nomogram Based on Metabolic Risk Score for Assessing Lymphovascular Space Invasion in Patients with Endometrial Cancer |
title_short | Development and Validation of a Nomogram Based on Metabolic Risk Score for Assessing Lymphovascular Space Invasion in Patients with Endometrial Cancer |
title_sort | development and validation of a nomogram based on metabolic risk score for assessing lymphovascular space invasion in patients with endometrial cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736227/ https://www.ncbi.nlm.nih.gov/pubmed/36497730 http://dx.doi.org/10.3390/ijerph192315654 |
work_keys_str_mv | AT wangjingyuan developmentandvalidationofanomogrambasedonmetabolicriskscoreforassessinglymphovascularspaceinvasioninpatientswithendometrialcancer AT lixingchen developmentandvalidationofanomogrambasedonmetabolicriskscoreforassessinglymphovascularspaceinvasioninpatientswithendometrialcancer AT yangxiao developmentandvalidationofanomogrambasedonmetabolicriskscoreforassessinglymphovascularspaceinvasioninpatientswithendometrialcancer AT wangjianliu developmentandvalidationofanomogrambasedonmetabolicriskscoreforassessinglymphovascularspaceinvasioninpatientswithendometrialcancer |